Carnitine deficiency aggravates carboplatin nephropathy through deterioration of energy status, oxidant/anti-oxidant balance, and inflammatory endocoids

被引:22
作者
Arafa, Hossam M. M. [1 ]
机构
[1] Al Azhar Univ, Fac Pharm, Dept Pharmacol & Toxicol, Cairo, Egypt
关键词
Carnitine deficiency; D-Carnitine; L-Carnitine; Carboplatin; Nephrotoxicity; ATP; Palmitate; TNF-alpha; NO; MPO;
D O I
10.1016/j.tox.2008.09.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have recently shown that carnitine deficiency could represent a risk factor in paracetamol hepatotoxicity. By the same token, D-carnitine-induced carnitine deficiency aggravated carboplatin nephropathy following challenge with a single dose (35 mg/kg, IP) of the platinum drug in male Swiss albino rats. The combination modality induced marked degenerative changes and severe inflammation in kidney tissues that surpassed either carboplatin or D-Carnitine given alone. The combined regimen synergistically increased the serum levels of creatinine, blood urea nitrogen (BUN), tumor necrosis factor alpha (TNF-alpha), palmitate, and kidney malondialdehyde (MIDA), adenosine triphosphate (ATP), nitric oxide (NO) contents as well as kidney myeloperoxidase (MPO) activity. The only parameter that has been notably decreased was the kidney reduced glutathione (GSH) level. Exaggeration by carnitine deficit of the deleterious effects of carboplatin is most probably ascribed to energy starvation. The reduction in kidney content of ATP parcels was associated with elevation of serum palmitate level that reflected debilitated fatty acid oxidation, and this further deteriorated energy resources in kidney tissues. Compromising the oxidant/anti-oxidant balance and modulating the release of some inflammatory endocoids namely, TNF-alpha and NO could also possibly account for such combinatorial detrimental toxicity. The current study was further extended to elucidate any possible nephroprotective effects of L-carnitine. Interestingly, carnitine supplementation ahead of carboplatin challenge ameliorated and almost normalized all the biochemical parameters and also mitigated the injurious effects of the cytotoxic drug. Thus, one could conclude that carnitine deficiency, whether being a causative clue or a sequela, might represent a risk factor in carboplatin nephropathy. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:51 / 60
页数:10
相关论文
共 49 条
[1]   L-carnitine halts apoptosis and myelosuppression induced by carboplatin in rat bone marrow cell cultures (BMC) [J].
Abd-Allah, ARA ;
Al-Majed, AA ;
Al-Yahya, AA ;
Fouda, SI ;
Al-Shabana, OA .
ARCHIVES OF TOXICOLOGY, 2005, 79 (07) :406-413
[2]  
Adams H., 1963, METHOD ENZYMAT AN, P539
[3]   Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer [J].
Akram, T ;
Maseelall, P ;
Fanning, J .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 192 (05) :1365-1367
[4]   Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model [J].
Al-Majed, AA ;
Sayed-Ahmed, MM ;
Al-Yahya, AA ;
Aleisa, AM ;
Al-Rejaie, SS ;
Al-Shabanah, OA .
PHARMACOLOGICAL RESEARCH, 2006, 53 (03) :278-286
[6]   Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues [J].
Aleisa, Abdulaziz M. ;
Al-Majed, Abdulhakeem A. ;
Al-Yahya, Abdulaziz A. ;
Al-Rejaie, Salim S. ;
Bakheet, Saleh A. ;
Al-Shabanah, Othman A. ;
Sayed-Ahmed, Mohamed M. .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2007, 34 (12) :1252-1259
[7]   Carnitine deficiency: a possible risk factor in paracetamol hepatotoxicity [J].
Arafa, Hossam M. M. .
ARCHIVES OF TOXICOLOGY, 2009, 83 (02) :139-150
[8]   L-carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats [J].
Boonsanit, Dolrudee ;
Kanchanapangka, Sumolaya ;
Buranakarl, Chollada .
NEPHROLOGY, 2006, 11 (04) :313-320
[9]   Hypocarnitinaemia induced by sodium pivalate in the rat is associated with left ventricular dysfunction and impaired energy metabolism [J].
Broderick T.L. .
Drugs in R & D, 2006, 7 (3) :153-161
[10]  
CARTER LA, 1995, J CHILD NEUROL, V10